Ionis Pharmaceuticals Inc [NASDAQ: IONS] closed the trading session at $57.49 on 2025-09-02. The day’s price range saw the stock hit a low of $49.13, while the highest price level was $57.9102.
The stocks have a year to date performance of 16.73 percent and weekly performance of 37.47 percent. The stock has been moved at 76.35 percent over the last six months. The stock has performed 33.60 percent around the most recent 30 days and changed 68.54 percent over the most recent 3-months.
If compared to the average trading volume of 1.90M shares, IONS reached to a volume of 16420211 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Ionis Pharmaceuticals Inc [IONS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IONS shares is $66.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IONS stock is a recommendation set at 1.69. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Ionis Pharmaceuticals Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 31, 2025. The new note on the price target was released on July 01, 2025, representing the official price target for Ionis Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $45, while H.C. Wainwright analysts kept a Buy rating on IONS stock.
The Price to Book ratio for the last quarter was 14.49, with the Price to Cash per share for the same quarter was set at 14.39.
IONS stock trade performance evaluation
Ionis Pharmaceuticals Inc [IONS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 37.47. With this latest performance, IONS shares gained by 33.60% in over the last four-week period, additionally plugging by 76.35% over the last 6 months – not to mention a rise of 64.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IONS stock in for the last two-week period is set at 84.26, with the RSI for the last a single of trading hit 2.78, and the three-weeks RSI is set at 2.00 for Ionis Pharmaceuticals Inc [IONS]. The present Moving Average for the last 50 days of trading for this stock 42.25, while it was recorded at 45.53 for the last single week of trading, and 35.50 for the last 200 days.
Ionis Pharmaceuticals Inc [IONS]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Ionis Pharmaceuticals Inc [IONS] shares currently have an operating margin of -28.13% and a Gross Margin at 96.85%. Ionis Pharmaceuticals Inc’s Net Margin is presently recorded at -28.36%.
Ionis Pharmaceuticals Inc (IONS) Capital Structure & Debt Analysis
According to recent financial data for Ionis Pharmaceuticals Inc. ( IONS), the Return on Equity (ROE) stands at -59.83%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -9.44%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Ionis Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -13.65%, showcasing its effectiveness in deploying capital for earnings.
Ionis Pharmaceuticals Inc (IONS) Efficiency & Liquidity Metrics
Based on Ionis Pharmaceuticals Inc’s (IONS) latest financial statements, the Debt-to-Equity Ratio is 3.13%, indicating its reliance on debt financing relative to shareholder equity.
Ionis Pharmaceuticals Inc (IONS) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Ionis Pharmaceuticals Inc. (IONS) effectively leverages its workforce, generating an average of -$250579.98 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.87% and a Quick Ratio of 2.86%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Ionis Pharmaceuticals Inc [IONS] stock
With the latest financial reports released by the company, Ionis Pharmaceuticals Inc posted -0.72/share EPS, while the average EPS was predicted by analysts to be reported at -0.98/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.26. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IONS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Ionis Pharmaceuticals Inc go to 26.17%.
Ionis Pharmaceuticals Inc [IONS]: Institutional Ownership
There are presently around $108.50%, or 109.29%% of IONS stock, in the hands of institutional investors. The top three institutional holders of IONS stocks are: FMR LLC with ownership of 21.89 million shares, which is approximately 15.0008%. VANGUARD GROUP INC, holding 13.85 million shares of the stock with an approximate value of $$659.89 million in IONS stocks shares; and VANGUARD GROUP INC, currently with $$602.41 million in IONS stock with ownership which is approximately 8.6598%.
